Liraglutide and a lipidized analog of prolactin-releasing peptide show neuroprotective effects in a mouse model of β-amyloid pathology

Holubová, M. and Hrubá, L. and Popelová, A. and Bencze, M. and Pražienková, V. and Gengler, S. and Kratochvílová, H. and Haluzík, M. and Železná, B. and Kuneš, J. and Hölscher, C. and Maletínská, L. (2019) Liraglutide and a lipidized analog of prolactin-releasing peptide show neuroprotective effects in a mouse model of β-amyloid pathology. Neuropharmacology, 144. pp. 377-387. ISSN 0028-3908

Full text not available from this repository.

Abstract

Obesity and type 2 diabetes mellitus (T2DM) are important risk factors for Alzheimer's disease (AD). Drugs originally developed for T2DM treatment, e.g., analog of glucagon-like peptide 1 liraglutide, have shown neuroprotective effects in mouse models of AD. We previously examined the neuroprotective properties of palm11-PrRP31, an anorexigenic and glucose-lowering analog of prolactin-releasing peptide, in a mouse model of AD-like Tau pathology, THY-Tau22 mice. Here, we demonstrate the neuroprotective effects of palm11-PrRP31 in double transgenic APP/PS1 mice, a model of AD-like β-amyloid (Aβ) pathology. The 7-8-month-old APP/PS1 male mice were subcutaneously injected with liraglutide or palm11-PrRP31 for 2 months. Both the liraglutide and palm11-PrRP31 treatments reduced the Aβ plaque load in the hippocampus. Palm11-PrRP31 also significantly reduced hippocampal microgliosis, consistent with our observations of a reduced Aβ plaque load, and reduced cortical astrocytosis, similar to the treatment with liraglutide. Palm11-PrRP31 also tended to increase neurogenesis, as indicated by the number of doublecortin-positive cells in the hippocampus. After the treatment with both anorexigenic compounds, we observed a significant decrease in Tau phosphorylation at Thr231, one of the first epitopes phosphorylated in AD. This effect was probably caused by elevated activity of protein phosphatase 2A subunit C, the main Tau phosphatase. Both liraglutide and palm11-PrRP31 reduced the levels of caspase 3, which has multiple roles in the pathogenesis of AD. Palm11-PrRP31 increased protein levels of the pre-synaptic marker synaptophysin, suggesting that palm11-PrRP31 might help preserve synapses. These results indicate that palm11-PrRP31 has promising potential for the treatment of neurodegenerative diseases. © 2018 Elsevier Ltd

Item Type: Journal Article
Journal or Publication Title: Neuropharmacology
Uncontrolled Keywords: /dk/atira/pure/subjectarea/asjc/3000/3004
Subjects:
Departments: Faculty of Health and Medicine > Biomedical & Life Sciences
ID Code: 129602
Deposited By: ep_importer_pure
Deposited On: 21 Dec 2018 15:20
Refereed?: Yes
Published?: Published
Last Modified: 20 Sep 2019 01:59
URI: https://eprints.lancs.ac.uk/id/eprint/129602

Actions (login required)

View Item View Item